{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer+Bone&page=81",
    "query": {
      "condition": "Cancer Bone",
      "page": 81
    },
    "page_size": 10
  },
  "pagination": {
    "page": 81,
    "page_size": 10,
    "total_count": 3411,
    "total_pages": 342,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer+Bone&page=82&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer+Bone&page=80&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-17T20:58:41.818Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00066599",
      "title": "Voriconazole in Preventing Fungal Infections in Children With Neutropenia After Chemotherapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Kidney Cancer",
        "Leukemia",
        "Lymphoma",
        "Multiple Myeloma and Plasma Cell Neoplasm",
        "Myelodysplastic Syndromes",
        "Myelodysplastic/Myeloproliferative Neoplasms",
        "Neuroblastoma",
        "Neutropenia",
        "Sarcoma"
      ],
      "interventions": [
        {
          "name": "voriconazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "11 Years",
        "sex": "ALL",
        "summary": "2 Years to 11 Years"
      },
      "enrollment_count": null,
      "start_date": "2003-06",
      "completion_date": "2004-06",
      "has_results": false,
      "last_update_posted_date": "2013-06-19",
      "last_synced_at": "2026-11-17T20:58:41.818Z",
      "location_count": 7,
      "location_summary": "Orange, California • San Diego, California • Bethesda, Maryland + 4 more",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00066599"
    },
    {
      "nct_id": "NCT00778375",
      "title": "Clofarabine Plus Low-Dose Cytarabine Induction and Decitabine Consolidation in Frontline Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Myeloid Leukemia",
        "Myelodysplastic Syndrome"
      ],
      "interventions": [
        {
          "name": "Clofarabine",
          "type": "DRUG"
        },
        {
          "name": "Cytarabine",
          "type": "DRUG"
        },
        {
          "name": "Decitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "60 Years and older"
      },
      "enrollment_count": 122,
      "start_date": "2008-10",
      "completion_date": "2015-01",
      "has_results": true,
      "last_update_posted_date": "2016-07-14",
      "last_synced_at": "2026-11-17T20:58:41.818Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00778375"
    },
    {
      "nct_id": "NCT00301834",
      "title": "Alemtuzumab, Fludarabine, and Busulfan Followed By Donor Stem Cell Transplant in Treating Young Patients With Hematologic Disorders",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Congenital Amegakaryocytic Thrombocytopenia",
        "Diamond-blackfan Anemia",
        "Leukemia",
        "Myelodysplastic Syndromes",
        "Severe Congenital Neutropenia"
      ],
      "interventions": [
        {
          "name": "alemtuzumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "busulfan",
          "type": "DRUG"
        },
        {
          "name": "cyclosporine",
          "type": "DRUG"
        },
        {
          "name": "fludarabine phosphate",
          "type": "DRUG"
        },
        {
          "name": "methotrexate",
          "type": "DRUG"
        },
        {
          "name": "methylprednisolone",
          "type": "DRUG"
        },
        {
          "name": "allogeneic bone marrow transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "allogeneic hematopoietic stem cell transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "peripheral blood stem cell transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "umbilical cord blood transplantation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "Up to 21 Years"
      },
      "enrollment_count": 35,
      "start_date": "2005-01",
      "completion_date": "2011-09",
      "has_results": true,
      "last_update_posted_date": "2017-09-28",
      "last_synced_at": "2026-11-17T20:58:41.818Z",
      "location_count": 2,
      "location_summary": "San Francisco, California • Madison, Wisconsin",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00301834"
    },
    {
      "nct_id": "NCT00049192",
      "title": "Oblimersen and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Myelogenous Leukemia, BCR-ABL1 Positive",
        "Chronic Phase Chronic Myelogenous Leukemia",
        "Relapsing Chronic Myelogenous Leukemia"
      ],
      "interventions": [
        {
          "name": "oblimersen sodium",
          "type": "BIOLOGICAL"
        },
        {
          "name": "imatinib mesylate",
          "type": "DRUG"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "15 Years and older"
      },
      "enrollment_count": 43,
      "start_date": "2002-11",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-06-04",
      "last_synced_at": "2026-11-17T20:58:41.818Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00049192"
    },
    {
      "nct_id": "NCT06465199",
      "title": "Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Atypical Teratoid/Rhabdoid Tumor",
        "Embryonal Tumor With Multilayered Rosettes",
        "Ewing Sarcoma",
        "Diffuse Intrinsic Pontine Glioma",
        "Osteosarcoma",
        "Neuroblastoma",
        "DIPG Brain Tumor"
      ],
      "interventions": [
        {
          "name": "Eflornithine (DFMO)",
          "type": "DRUG"
        },
        {
          "name": "AMXT 1501 Dicaprate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Milton S. Hershey Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "26 Years",
        "sex": "ALL",
        "summary": "Up to 26 Years"
      },
      "enrollment_count": 265,
      "start_date": "2026-05-13",
      "completion_date": "2035-05",
      "has_results": false,
      "last_update_posted_date": "2026-09-03",
      "last_synced_at": "2026-11-17T20:58:41.818Z",
      "location_count": 14,
      "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Hartford, Connecticut + 11 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Hartford",
          "state": "Connecticut"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06465199"
    },
    {
      "nct_id": "NCT00708019",
      "title": "Improving Cancer Pain Management Through Self-Care",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Cancer",
        "Pain"
      ],
      "interventions": [
        {
          "name": "PRO-SELF PLUS Pain Management Program",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 185,
      "start_date": "2007-12",
      "completion_date": "2013-06",
      "has_results": true,
      "last_update_posted_date": "2016-05-05",
      "last_synced_at": "2026-11-17T20:58:41.818Z",
      "location_count": 2,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00708019"
    },
    {
      "nct_id": "NCT07091019",
      "title": "A Real-world Chronic Myelogenous Leukemia (CML) Patient Disease Registry to Describe Patient Experience and Clinical Outcomes Among Patients With CML Receiving Approved First or Second Line Tyrosine Kinase Inhibitor (TKI) Therapy",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Chronic Myelogenous Leukemia - Chronic Phase"
      ],
      "interventions": [
        {
          "name": "TKIs",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 1000,
      "start_date": "2025-12-17",
      "completion_date": "2033-04-20",
      "has_results": false,
      "last_update_posted_date": "2026-07-20",
      "last_synced_at": "2026-11-17T20:58:41.818Z",
      "location_count": 17,
      "location_summary": "Birmingham, Alabama • Stockton, California • Torrance, California + 13 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Stockton",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Stamford",
          "state": "Connecticut"
        },
        {
          "city": "Pensacola",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07091019"
    },
    {
      "nct_id": "NCT00899665",
      "title": "Proteases in Patients With Prostate Cancer That Has Spread to the Bone",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Anemia",
        "Metastatic Cancer",
        "Myelodysplastic Syndromes",
        "Precancerous Condition",
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "fluorescence in situ hybridization",
          "type": "GENETIC"
        },
        {
          "name": "microarray analysis",
          "type": "GENETIC"
        },
        {
          "name": "molecular diagnostic method",
          "type": "GENETIC"
        },
        {
          "name": "immunohistochemistry staining method",
          "type": "OTHER"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "immunoscintigraphy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "GENETIC",
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "Barbara Ann Karmanos Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "40 Years and older · Male only"
      },
      "enrollment_count": 31,
      "start_date": "2001-07",
      "completion_date": "2008-01",
      "has_results": false,
      "last_update_posted_date": "2014-02-11",
      "last_synced_at": "2026-11-17T20:58:41.818Z",
      "location_count": 1,
      "location_summary": "Detroit, Michigan",
      "locations": [
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00899665"
    },
    {
      "nct_id": "NCT07722611",
      "title": "A Clinical Trial of Bomedemstat in Participants With Polycythemia Vera (MK-3543-025).",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Polycythemia Vera"
      ],
      "interventions": [
        {
          "name": "Bomedemstat",
          "type": "DRUG"
        },
        {
          "name": "Ruxolitinib",
          "type": "DRUG"
        },
        {
          "name": "Ropeginterferon alfa-2b",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 380,
      "start_date": "2026-10-29",
      "completion_date": "2032-11-30",
      "has_results": false,
      "last_update_posted_date": "2026-11-13",
      "last_synced_at": "2026-11-17T20:58:41.818Z",
      "location_count": 4,
      "location_summary": "Newark, Delaware • Columbia, Maryland • Eugene, Oregon + 1 more",
      "locations": [
        {
          "city": "Newark",
          "state": "Delaware"
        },
        {
          "city": "Columbia",
          "state": "Maryland"
        },
        {
          "city": "Eugene",
          "state": "Oregon"
        },
        {
          "city": "Charlottesville",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07722611"
    },
    {
      "nct_id": "NCT00030667",
      "title": "Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of Childhood",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Childhood Desmoplastic Small Round Cell Tumor",
        "Childhood Synovial Sarcoma",
        "Gastrointestinal Stromal Tumor",
        "Lung Metastases",
        "Recurrent Childhood Soft Tissue Sarcoma",
        "Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor",
        "Recurrent Neuroblastoma",
        "Recurrent Osteosarcoma"
      ],
      "interventions": [
        {
          "name": "imatinib mesylate",
          "type": "DRUG"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "pharmacological study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "Up to 30 Years"
      },
      "enrollment_count": 100,
      "start_date": "2002-05",
      "completion_date": "2005-12",
      "has_results": false,
      "last_update_posted_date": "2015-04-15",
      "last_synced_at": "2026-11-17T20:58:41.818Z",
      "location_count": 1,
      "location_summary": "Arcadia, California",
      "locations": [
        {
          "city": "Arcadia",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00030667"
    }
  ]
}